NeoStem falls, author questions AMR-001 after study results

|By:, SA News Editor

NeoStem (NBS -11.1%) started the day in positive territory but quickly faded into the red and is now down double-digits.

It looks likely that an article by SA contributor Probio Invest is weighing on the shares.

Probio says a study that showed autologous stem cells did not boost heart function "clearly does not bode well for NBS' AMR-001."